Affymax to make multiple presentations on preclinical and clinical data of Hematide

Oct 23 2009

Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.

Affymax’s drug, Hematide™, is currently in development with Takeda Pharmaceutical Company Limited for the treatment of anemia associated with chronic renal failure. Affymax and investigators will make multiple presentations highlighting Hematide preclinical and clinical data in various treatment settings. These include preliminary results of a Phase 2 trial in hemodialysis (HD) patients who are not on an erythropoiesis stimulating agent (ESA), and interim results from an ongoing Phase 2 study in patients with antibody-mediated pure red cell aplasia (Ab+PRCA).

Details of Hematide presentations at ASN are as follows:

*Note: All times are listed in Pacific Time

Company Webcast

Affymax will host an investor webcast with Dr. Richard Lafayette, clinical chief of nephrology and associate professor of medicine at Stanford University Medical Center, and Dr. Iain MacDougall, nephrology consultant at the Department of Renal Medicine, King’s College Hospital. Dr. Lafayette will provide background on managing anemia in patients with chronic kidney disease. Dr. MacDougall will discuss pure red cell aplasia (PRCA) a rare, serious and debilitating autoimmune disorder, which can occur when the body produces neutralizing antibodies to the currently marketed recombinant human erythropoietins.